Floatz logo

Factor Ix

Hemorrhagic Disorders

National Heart, Lung, and Blood Institute (NHLBI)Phase 3Dormant
BB
64/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
49/ 100
Competitive Position
95/ 100

Competitive context

7 Active assets in the Hemorrhagic Disorders cohort.

Asset / SponsorPhaseRating
Damoctocog Alfa Pegol
Bayer
Phase 4BBB
Rivaroxaban
Brigham and Women's Hospital
Phase 4BBB
WARFARIN
Asan Medical Center
Phase 4BBB
Recombinant Human Plasminogen Activator
Hamilton Health Sciences Corporation
Phase 4BB
HUMAN FIBRINOGEN
University Health Network, Toronto
Phase 4BB

View all 24 →

Same molecule, other indications

Factor Ix is also rated in:

hemophilia BDormant
A
Indicative ·
84 / 100
View asset →
hemophilia BDormant
BBB
Indicative ·
75 / 100
View asset →
hemophilia ADormant
BBB
Indicative ·
72 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →